Poniard Pharmaceuticals, a biopharmaceutical company, has reached its enrollment target of 400 patients in the Spear trial.

This global, pivotal Phase III trial is evaluating the efficacy and safety of picoplatin in patients with recurrent small cell lung cancer (SCLC) who have failed prior platinum-containing first-line chemotherapy or who have progressed within six months of first-line therapy. Patients have been enrolled at more than 100 clinical trial sites in 16 countries in Europe, South America and Asia.